Finally, in addition to breast cancer, the significance of our finding should be further studied also in other cancers where BPs are much used or where low tumor TLR9 expression is associated with poor outcome, such as renal cell carcinoma [64]. This evidence concerns the gene TLR9 and renal cell carcinoma.